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 معاجلة الرضع و األطفال املخالطني للمرضى املصابني مبرض
السل املعدي
جورج بول، اأمل �سيف املعنية، بادماموهان جاناردانا كوروب
امللخ�ص: التحقيق وعالج االأ�سخا�ض املخالطني ملر�سى ال�سل )الدرن( ي�سكل مفتاح مكافحة هذا املر�ض يف البلدان التي تعد حاالت 
االإ�سابة فيها منخف�سة. �سلطنة عمان كاأحدى الدول املعروفة بانخفا�ض حاالت وقوع ال�سل، اعتمدت تطبيق التحقيق ومعاجلة االأ�سخا�ض 
املت�سلني باملر�سى امل�سابني بهذه العدوى كاإحدى اال�سرتاتيجيات املهمة ملكافحة ال�سل. على الرغم من ذلك، ال توجد مبادئ توجيهية 
وا�سحة للتحقيق واملعاجلة ال �سيما فيما يتعلق باالأطفال املخالطني ملر�سى ال�سل. اإن الف�سل يف معاجلة مثل هذا االت�سال عند االأطفال 
يعد فر�سة �سائعة للحد من انت�سار املر�ض بني ال�سكان الذي قد يعر�سهم خلطر التقدم ال�رسيع للمر�ض وم�ساعفاته. هذا املقال يحاول 
توفري نهج موجز عن عملية التحقيق وعالج الر�سع واالأطفال املخالطني ملر�سى ال�سل ويناق�ض باإيجاز اخلطوات اال�سا�سية يف جمموعة 
من ال�سيناريوهات املحتملة. 
مفتاح الكلمات: ال�سل؛ االأطفال؛ عدوى �سل خاف؛ اختبار التوبركولني؛ ُعمان.
abstract: Contact investigation and management form the key for tuberculosis (TB) control in countries 
with a low tuberculosis incidence. Oman, with a low TB incidence, has implemented contact investigation 
and management as one important strategy to control TB. However there is a lack of clear guidelines for the 
investigation and treatment of contacts, especially with regard to children who are contacts of TB cases. The failure 
to manage children in contact with infectious TB cases indicates a missed opportunity to prevent TB disease in a 
population which is prone to progress rapidly to severe and complicated illness. This article attempts to provide a 
concise and practical approach for managing infants and children who are in contact with TB patients. Essential 
steps in a variety of possible scenarios are briefly discussed. 
Keywords: Tuberculoses; Children; Latent Tuberculosis Infection; Tuberculin Tests; Oman.
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Investigation of people exposed to cases of infectious tuberculosis (TB), also called contact investigation, is the key to TB control, 
especially in countries with a low incidence of TB. 
Recent literature suggests that contact investigation 
also merits serious consideration as a means to 
improve early case detection and decrease the 
transmission of Mycobacterium tuberculosis (MTB) 
even in high-incidence areas.1 Oman, with a low TB 
incidence and high Bacillus Calmette-Guérin (BCG) 
vaccine coverage at birth, has implemented contact 
investigation and management as an important 
strategy for the control of TB.2 The incidence of 
sputum smear-positive TB in Oman was 5.1 per 
100,000 Omanis in 2011. Incidence rates of TB as 
well as sputum smear-positive TB has shown an 
almost static trend over the past decade [Figure 1].3
Contact investigation and the management of 
children who are exposed to an infectious adult 
source case are considered the most efficient 
ways to prevent paediatric TB disease. Missed 
opportunities to prevent cases of TB disease in 
children can be due to a delay in the diagnosis or 
management of the adult source case, a delay in the 
reporting of a source case to the local public health/
TB control authority, a failure to identify a child 
during contact investigations, or lack of knowledge 
on how to manage and follow-up paediatric contact 
cases.4
Although contact management is an important 
strategy, there is a lack of clear guidelines for the 
investigation and treatment of contacts, especially 
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children who are in contact with TB patients that 
would be helpful in the Omani context.
The manifestations of TB infection, after 
exposure to a person with active infectious TB,  are 
very different in infants and children. Therefore, 
the management should vary from that of an adult 
who is exposed to the same. Children pose three 
unique challenges to TB control. First, the diagnosis 
of TB disease in children under 5 years of age can 
be difficult because they often have nonspecific 
signs and symptoms and a paucity of Mycobacteria. 
Second, TB in children is considered a sentinel 
event usually indicating recent transmission. Finally, 
children, especially infants, are at an increased risk 
of progressing from latent TB infection (LTBI) to 
active and sometimes severe TB disease.
Infection with MTB is usually the result of 
inhaling into the lungs infected droplets produced 
by someone who has laryngeal TB or pulmonary 
TB and is coughing. The source of infection for 
most children is thus an infectious adult in their 
close environment, usually the household. This 
exposure leads to the development of a primary 
parenchymal lesion (Ghon’s focus) in the lung 
which spreads to the regional lymph node(s).6 The 
immune response (delayed hypersensitivity and 
cellular immunity) develops about 4–6 weeks after 
the primary infection. In most cases, the immune 
when it comes to children. This is primarily due to 
a lack of awareness regarding the various aspects of 
childhood TB. In addition, TB contact investigations 
typically require interdependent decisions which 
sometimes are based on incomplete data. Simple 
decision trees are often not applicable and the 
decision making is often a complex process.5 
In Oman, these challenges are more prominent 
in the primary care setting where most of the 
contact screening and management of TB cases are 
undertaken. Due to these factors, although an outline 
for managing paediatric contacts of contagious TB 
is provided in the TB manual published by the 
Omani Ministry of Health, the authors have noted 
that a significant proportion of formal and informal 
consultations are done in this regard.2 Thus, there is 
an obvious need to provide the essential principles 
and approach to such cases in a clear and concise 
manner for the primary healthcare setting in Oman. 
This outline is derived from current practice in a 
tertiary care setting in Oman which is essentially 
based on the latest guidelines issued by the World 
Health Organization (WHO) and the Centers for 
Disease Control and Prevention (CDC) in Atlanta, 
Georgia, USA. This is not an exhaustive review of 
all the relevant publications nor is it a national TB 
programme guideline. Our objective is to provide 
a practical approach for managing infants and 
Figure 1: Annual tuberculosis incidence among the Omani population (per 100,000). 
TB = tuberculosis.
Adapted from: Annual Statistical Reports, Ministry of Health, Muscat, Oman.
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response stops the multiplication of TB bacilli 
at this stage. However, a few dormant bacilli may 
persist. The primary infection may be associated 
with complications, especially in children under 5 
years of age.7,8 The parenchymal lesion may enlarge 
and caseate, or nodes may enlarge and compress 
or erode through a bronchus, causing wheezing, 
segmental pneumonia or atelectasis. The occult 
subclinical bacteremia that usually accompanies 
primary infection may result in severe TB diseases 
such as disseminated TB or central nervous system 
TB. The risk of TB disease and severe forms of it 
after exposure is inversely related to age [Table 1].7
Children living in close contact with a source 
case of smear-positive pulmonary TB or laryngeal 
TB are at particular risk of TB infection and disease. 
No safe exposure time to airborne MTB has been 
established. If a single bacterium can initiate an 
infection leading to TB disease, then even the 
briefest exposure entails a theoretical risk. The 
risk of infection is greatest in the case of close and 
prolonged contact, such as the contact an infant or 
toddler has with the mother or other caregivers in 
the household. The risk of developing disease after 
infection is much greater for infants and young 
children under 5 years of age than it is for children 
aged 5 years or above. The risk of progression 
gradually decreases through childhood.7 Also, 
infants and younger children are more likely to 
develop life-threatening forms of TB, especially 
meningeal and disseminated disease, compared to 
older children and adults.9
If disease does develop, it usually does so within 
two years of infection, but in infants the time-lag 
can be as short as a few weeks. Isoniazid (INH) 
preventive therapy for young children with infection 
who have not yet developed disease will greatly 
reduce the likelihood of TB during childhood with 
a risk reduction of 70–90%.10 A tuberculin skin test 
(TST), interferon gamma release assay (IGRA), or 
chest X-ray (CXR) is the best method to screen for 
TB disease among contacts.6,9
Terminology
Some of the terminologies used in this article need 
explanation.2,9
• Close contact: A child living in the same household 
as a source case (e.g. the child’s caregiver) or who is 
in frequent contact with a source case.
• Contagious or infectious TB: Pulmonary TB or 
laryngeal TB. 
• Exposure: A situation in which a child has 
significant contact with an adult infected with 
a contagious form of TB. A child exposed to 
MTB does not necessarily become infected. The 
recommended minimum period between the most 
recent exposure and tuberculin skin testing should 
be 8–10 weeks.
• Exposure history and time frame: The start of 
infectious period for an index case cannot be 
determined with precision through the available 
methods. However, on the basis of expert opinion, 
a date three months prior to the date of diagnosis is 
to be assigned as the starting date for infection and 
this duration should be considered as the infectious 
period.9 In those circumstances where there is a 
longer duration of symptoms or protracted illness, 
it is wiser to have an earlier start based on the 
duration of the illness. 
• LTBI: A condition in which MTB has entered 
the body and typically has elicited immune 
responses. LTBI is an asymptomatic condition 
that follows the initial infection; the infection is 
still present but is dormant and believed not to 
be currently progressive or invasive. The only sign 
of TB infection is a positive reaction to the TST 
Table 1: Average age-specific risk for disease 


























TB meningitis or miliary disease 0.5
TB = tuberculosis.
Adapted from Marais et al.7
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for one month or more) and anti-neoplastic agents.
When the induration following a TST (Mantoux 
test) is ≥10 mm, it should be considered as positive 
in the following situations: children with frequent 
exposure to adults at high risk; birth in or recent 
immigration (<5 years) from a high-prevalence 
country; children who had travelled or been 
exposed to visitors from high-prevalence countries, 
or children with malnutrition, chronic renal failure, 
diabetes mellitus or lymphoma.
In the case of children exposed to contagious 
TB, the management should be adapted according 
to the age of the child and his/her immune status.5,9 
The investigations and management of newborns 
and children who are contacts of TB cases would 
differ; thus, the discussion should focus on the 
following settings: (1) a newborn whose mother or 
other household contact has a contagious form of 
TB or LTBI; (2) children less than 5 years of age with 
exposure to a contagious case of TB or more than 
5 years of age with exposure to a contagious case of 
TB; (3) children with exposure to a non-contagious 
case of TB, another child with TB disease, or an 
adult with MDRTB, or (4) a child who has a contact 
who is known to be HIV-infected.
Management of 
Newborns
In a newborn whose mother or other household 
contact has a contagious form of TB, the 
management should also vary according to the 
situation. If the mother is known or suspected of 
having TB disease, a maternal evaluation to rule out 
pulmonary or extra pulmonary disease including 
uterine TB needs to be done. An HIV serology 
should be undertaken if her prenatal screening is 
not done or is unavailable. A BCG vaccine should 
not be given to a newborn. However, an evaluation 
for congenital TB should be carried out if the 
newborn is symptomatic or in the cases where the 
mother is still acid fast bacilli (AFB)-positive or 
has disseminated disease that was not treated or 
was partially treated. An evaluation should also be 
carried out in cases of maternal endometrial TB 
regardless of treatment status with CXR, gastric 
aspirates for AFB and a TB culture of 3 early morning 
consecutive samples, an abdominal ultrasound 
or a lumbar puncture followed by submitting 
cerebrospinal fluid for AFB and TB cultures.9 If the 
or a positive result with the currently available 
blood test—the IGRA. For practical purposes, a 
child with LTBI is someone with a positive TST, 
no clinical evidence of disease, and a CXR that is 
either normal or demonstrates evidence of remote 
infection, such as a calcified parenchymal nodule 
and/or a calcified intrathoracic lymph node. 
Although these abnormal CXR findings do not 
strictly come under the definition of LTBI, it is also 
not considered an active disease and it is prudent 
to treat it as LTBI. People with a latent TB infection 
are not infectious; however, some of them develop 
TB disease depending on their immune status and 
the presence of other risk factors.8
• TB disease: The diagnosis is based on symptoms, 
radiological changes and microscopy. Positive 
culture results for MTB are typically interpreted 
as both the indication and the confirmation 
of TB disease. For persons whose immune 
systems are weak, especially those with human 
immunodeficiency virus (HIV) infection, the risk of 
developing TB disease is significantly higher than it 
is for persons with normal immune systems.
• Multidrug resistant TB (MDRTB): This is defined 
as TB caused by MTB resistant in vitro to the 
effects of isoniazid and rifampicin, with or without 
resistance to any other drugs.11
Diagnosis
The definition used here for a positive TST is based 
on the CDC guidelines.9 Oman is a country with 
a low prevalence of TB and high BCG coverage at 
birth; thus, the interpretation of a positive test has 
to be done cautiously. There is neither a compelling 
need to adopt a lower cut-off for positivity, nor is it 
advisable to use a higher cut-off. Therefore, a special 
cut-off seems warranted in the context of TB 
control in Oman. When the induration following 
a TST (Mantoux test) is ≥5 mm, it should be 
considered as positive in the following situations: 
children in close contact with known/suspected 
contagious cases of TB; children suspected to 
have TB disease; findings in CXR consistent with 
active/previously active TB; clinical evidence of TB 
disease; children with HIV infection or immune 
deficiency states; children receiving immune 
suppressive therapy including immunosuppressive 
doses of corticosteroids (>15 mg prednisolone/day 
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newborn is found to have TB disease, then treatment 
should be initiated promptly with the appropriate 
regimen in consultation with a paediatric infectious 
diseases specialist. If congenital TB is excluded, 
treatment for LTBI with INH (10 mg/Kg/day) 
should be administered until the infant is at least 3 
months of age and then a TST should be performed. 
If the repeated TST is positive, the child should be 
reassessed for active TB. If the disease is absent, a 
full course of treatment for LTBI should be given 
based on the sensitivities of the index strain. If the 
TST is negative and TB disease is ruled out, and the 
mother or the household contact has become non-
contagious, then the INH should be stopped and a 
BCG vaccine administered to the baby who should 
then be followed-up on a monthly basis.9
For infection control, the newborn should be 
separated from any active TB case in the household 
including his/her mother during the evaluation 
period and any mother/adult contact should wear 
a facemask while handling the baby while following 
the isolation precautions. Once the baby is on INH 
and the mother or adult source is on full treatment, 
there is no need to separate the baby, and the mother 
can again breastfeed the baby.9,12 Management is 
different if the mother has MDRTB, as is described 
later in this article.
In a newborn whose mother or other household 
contact has LTBI, the mother or household contact 
should be treated for LTBI. Since a positive TST 
result could be a marker for an unrecognised case 
of contagious TB within the household, other 
household members should be investigated for 
TB disease/LTBI. The newborn needs no special 
evaluation, and a BCG vaccine can be given if no 
infectious case of TB disease is identified in the 
household.9
Management of Children 
under 5 Years
In the management of children under 5 years of age 
with exposure to a contagious case of tuberculosis, 
the investigation for TB disease should include a 
TST (gastric juice for AFB is required only if the 
CXR is abnormal or the child is symptomatic). If 
a child has TB disease, the child should be started 
on a regimen of 3–4 anti-TB drugs in consultation 
with a paediatric infectious disease specialist and 
followed up. If TB disease is ruled out, all children 
in this category should be started on INH. Further 
follow-up depends on the child’s TST status. If TB 
disease is ruled out, but the child has a positive 
TST, INH should be continued for 9 months. 
These children should be followed-up closely and 
reinvestigated for TB disease after 3 months. If the 
reinvestigation rules out TB disease, INH should 
be continued for 9 months and, if the child has 
impaired immunity, INH should be continued for 
12 months. There is no need to repeat the TST at 3 
months while reinvestigating for TB disease. If TB 
disease is ruled out and the TST is negative, INH 
should be continued and the child reinvestigated 
after three months. If the reinvestigation rules out 
TB disease, and if the repeat TST is negative, then 
INH should be stopped and the child followed-up 
[Figure 2].5,9
Management of Children 
over 5 Years
In children above 5 years of age with exposure 
to a contagious case of TB, the child needs to be 
investigated for TB disease; however, gastric juice 
for AFB or sputum examination is required only if 
the CXR is abnormal or if the child is symptomatic. 
If TB disease is ruled out and TST is found to be 
negative, there is no need for any treatment in 
the case of a child with a normal immune status. 
However, if the child has impaired immunity, then 
s/he should be started on INH prophylaxis. These 
children should be followed-up and reinvestigated 
for TB disease after three months.5,9
If TB disease is ruled out again but the repeat 
TST is positive, INH should be started and the case 
treated as LTBI. The duration of treatment should 
be decided on the basis of the child’s immune status. 
If the TST is negative, there is no need for any 
treatment or follow-up.5 If the child is HIV-positive, 
INH should be continued for one year [Figure 3].2
In children with exposure to a non-contagious 
case of TB, an investigation is required because 
there could be an unrecognised contagious case in 
the household.5,9 If the TST is positive, they should 
be managed as a case of LTBI.2 
In a child exposed to another child with TB 
disease, the TB disease in children need not be 
considered contagious unless the child has a 
cavitating adult form of pulmonary TB or has 
laryngeal TB. Both these conditions are very rare 
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Figure 2: Flowchart showing the proposed management of children of less than 5 years of age with exposure to a 
contagious case of tuberculosis.
TB = tuberculosis; TST = tuberculin skin test; CXR = chest X-ray; INH = isoniazid; HIV = human immunodeficiency virus.
Children and Multidrug 
Resistant Tuberculosis
In a child with exposure to an adult with MDRTB, 
the optimal therapy for those with LTBI caused by 
an organism resistant to INH and rifampicin is not 
known. In these circumstances, multidrug regimens 
have been used. Drugs that are considered for these 
regimens include pyrazinamide, fluroquinolone, 
and ethambutol depending on the susceptibility of 
the isolated organisms. Consultation of infectious 
disease experts for the management of such children 
is recommended.11,12
and so there is no contraindication for children with 
these types of TB disease to attend schools or play 
with normal children.5,9 
For the same reason, when children are 
admitted for the investigation of TB, there is no 
need to keep them in isolation rooms unless there is 
some uncertainty regarding the status of attendants 
who are quite often the source of TB transmission 
in paediatrics wards. Children with TB are rarely 
contagious, but that is not necessarily the case with 
their caregivers.12,13
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HIV-Infected Children
If the child contact is HIV-infected and 
asymptomatic, then INH therapy should be 
considered for all ages, including those who are 
5 years and older. As with other contacts, active 
disease should be ruled out before providing HIV-
infected children with INH treatment. HIV-infected 
children who have symptoms should be carefully 
evaluated for TB disease as they are at an increased 
risk of developing active disease after TB exposure/
infection; therefore, the use of INH is justified once 
active TB has been excluded.12
Therapies
INH is widely used as the drug of choice for LTBI 
treatment with the standard recommended dose 
being 10–15 mg/Kg/day (maximum dose: 300 mg/
day). Young children eliminate INH faster than 
older children and adults and, consequently, require 
a higher dosage to achieve similar levels. The drug 
is well absorbed orally and is best absorbed when 
consumed on an empty stomach. The primary 
possible adverse reactions include hepatitis (age-
related), peripheral neuropathy and hypersensitivity 
reactions. Other reactions include optic neuritis, 
Figure 3: Flowchart showing the proposed management of children over 5 years of age with exposure to a contagious 
case of tuberculosis.
TB = tuberculosis; TST = tuberculin skin test; CXR = chest X-ray; INH = isoniazid; HIV = human immunodeficiency virus.
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number of studies have shown that IGRAs perform 
well in immunocompetent children of 4 years of 
age and older.15 Implementation of IGRA testing 
in children can be done with less caution for those 
who are ≥5 years old. This is because they are less 
likely to develop active TB or severe forms of it 
compared to children who are under 5 years old 
and in them it is logistically easier (e.g. in the ability 
to draw sufficient quantities of blood).16 Evaluation 
of this test has been hampered by the lack of a gold 
standard for LTBI, and limited paediatric data on 
their use. It appears that it is more specific than the 
TST and may be useful for evaluating TST-positive 
patients at low risk of true LTBI. Moreover, it may 
provide valuable information on sensitivity if used 
in addition to the TST in immunocompromised 
patients, very young children, and those in close 
contact with infectious adults.17 Additional larger 
studies are needed to evaluate the performance of 
IGRAs in children.16
Conclusion
In countries with low TB incidence, such as 
Oman, that are working towards TB elimination, 
there is an emphasis on contact investigation and 
management. The process of investigation and 
management for children who are contacts of 
contagious TB have been described and simple 
algorithms provided for easy application in the 
primary care setting. The importance of Mantoux 
testing and its timing have been highlighted, along 
with a brief summary of interferon testing and 
latent TB infection treatment. We have provided a 
concise and practical approach aimed at enhancing 
contact investigation effectiveness and management 
of infants and children who are in contact with a 
contagious case of TB.
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